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Mitral valve prolapse (MVP [MIM 147700]) is among
the most common cardiovascular abnormalities, affect-
ing ∼2%–8% of the population (Levy and Savage 1987).
In fact, this abnormality is believed to affect as many as
15%–20% of young women and a significantly lower
proportion (1%–3%) of men, suggesting to some cli-
nicians that this abnormality is, in most cases, a trivial
variant of normal valve architecture. However, since
some adult patients ultimately require mitral valve re-
placement (Carpentier et al. 1980; Alpert et al. 1998)
and since MVP is commonly associated with well-known
clinical entities such as Marfan syndrome and Ehlers-
Danlos syndrome (Glesby and Pyeritz 1989), others be-
lieve MVP to be a form of significant heart disease (Bou-
darias 1991).
MVP is described as excessive mitral valve tissue that
leads to billowing of the mitral valve leaflets, with or
without prolapse and mitral regurgitation (MR) (Frable
1969; Kern and Tucker 1972; Barlow and Pocock 1979;
Virmani et al. 1987). Clinically, the diagnosis is sus-
pected when a mid-systolic click and/or late-systolic car-
diac murmur are auscultated (Barlow et al. 1963; Barlow
and Pocock 1979; Perloff et al. 1986). The diagnosis is
confirmed by echocardiography (Nishimura et al. 1985;
Levine et al. 1988), and occasionally there is disparity
in the physical exam findings and echocardiographic
findings (Weiss et al. 1975). In some families, several
affected individuals can be identified, with inheritance
usually being autosomal dominant (Shappell et al. 1973;
Weiss et al 1975; Bareiss 1976; Cooper and Abinader
1981; Strahan et al. 1983). Age dependence and sex
dependence (Devereux et al. 1982) also have been noted.
In addition, X-linked inheritance has been reported in
a forme fruste of MVP, called “severe myxomatous val-
vular dystrophy,” which has been mapped to Xq28
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(Kyndt et al. 1998). In families with MVP, clinical het-
erogeneity is quite significant, with severely abnormal
valves noted in some and with nearly normal valves seen
in other members of the same family (Zuppiroli et al.
1998). In addition, most patients are asymptomatic, al-
though a portion of the affected individuals have severe
symptoms of congestive heart failure with severe MR.
Some individuals (usually teenage girls) have a person-
ality type that includes a high-strung style, and these
individuals commonly complain of palpitations, chest
pain, and dizziness (which is due to hyperventilation).
In this issue of the Journal, Disse et al. (1999) localize
the first locus for autosomal dominant myxomatous
MVP (MMVP) to chromosome 16p11.2-p12.1. This
work highlights a number of important points. First, the
authors have avoided issues of uncertain diagnosis, by
selecting severely affected index cases in whom mitral
valve–replacement surgery was required. In addition,
only first-degree relatives were recruited for evaluation,
and each relative underwent double-blind echocardio-
graphic analysis, thus allowing for consistent diagnostic
criteria. This approach also enabled the authors to max-
imally diagnose family members, avoiding the insensi-
tivity noted when only family history is used. This point
previously had been highlighted by Michels et al. (1985,
1992), who showed that the use of family history alone
identified 6% of relatives of probands as having dilated
cardiomyopathy (DCM), whereas echocardiograms per-
formed on all family members irrespective of history
identified 20% of these members as being affected, albeit
asymptomatic in most cases.
Another important finding by Disse et al. is that, in
the families studied, equal numbers of men and women
were affected (i.e., there were no sex-dependent differ-
ences), a finding that differs from the female predomi-
nance reported by others. Whether clinical signs, symp-
toms, and outcomes differ between the sexes was not
studied by Disse et al., however.
Because of the large distance of the MMVP1 critical
region, which now is considered to be in the 5–34-cM
range, a positional candidate-gene approach has been
used by Disse et al., which requires a detailed under-
standing of the clinical and histopathological phenotype.
As these authors note, genes involved in the structure
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or development of the atrioventricular valves are obvi-
ous possibilities. Other reasonable choices are needed,
however. Hints with regard to candidate-gene selection
could come from successful studies of other cardiovas-
cular disorders. My colleagues and I recently have de-
scribed the “final common pathway” hypothesis of car-
diovascular disease, which suggests that hereditary
cardiovascular diseases with similar phenotypes and ge-
netic heterogeneity occur because of abnormalities of
genes encoding proteins either with similar functions or
participating in a common pathway cascade (Towbin
1999; Towbin et al. 1999). For instance, all of the
genes responsible for hypertrophic cardiomyopathy
(HCM)—a cardiac disorder in which thickening of both
the left ventricle and interventricular septum occurs in
association with diastolic dysfunction, hypercontractile
systolic function, and myofiber disarray (Maron
1997)—encode proteins composing the sarcomere (i.e.,
contractile units of the heart) (Thierfelder et al. 1994).
In addition, all of the genes responsible for inherited
forms of ventricular arrhythmias (as in the long QT syn-
dromes and Brugada syndrome) are due to mutations
in cardiac ion channels (Wang et al. 1998; Chen et al.
1998). Recently, I have suggested that abnormalities of
cytoskeletal proteins will underlie the development of
dilated cardiomyopathy (DCM) and that, since the sar-
comere and cytoskeleton are connected via dystrophin
and the actin cytoskeleton, intermediate phenotypes are
likely (Towbin 1998). The identification of mutations in
actin that are near the dystrophin-binding site and that
cause DCM (Olson et al. 1998) and of mutations at the
sarcomeric end that cause HCM (Mogensen et al. 1999)
further support this hypothesis.
Taking advantage of the final common pathway hy-
pothesis, one could evaluate previously identified genetic
mutations in patients with MVP associated with other
diseases. For years there has been speculation that con-
nective-tissue abnormalities cause MVP (Glesby and
Pyeritz 1989; Henney et al. 1989; Tamura et al. 1995).
This speculation has been supported by a variety of stud-
ies. The fibrillin-1 gene, when mutated, causes Marfan
syndrome in which MVP and aortic-root dissection are
common (Glesby and Pyeritz 1989). This connective tis-
sue–encoding gene gives rise to a wide variety of clinical
phenotypes when mutated, including classic Marfan syn-
drome (Lee et al. 1991; Towbin and Roberts 1998), with
its pleiotropic findings that include cardiac, vascular,
bone/skeletal, and ocular abnormalities, to pure skeletal
abnormalities, to pure cardiovascular phenotypes (i.e.,
aortic aneurysm) (Putnam et al. 1995; Sood et al. 1996;
Furthmayr and Francke 1997). Another cardiovascular
disorder associated with connective-tissue abnormalities
is Williams syndrome (Williams et al. 1961; Beuren
1972; Ewart et al. 1993; Morris 1998), which is asso-
ciated with mental retardation, dysmorphisms, and su-
pravalvar aortic stenosis associated with elastin muta-
tions. Mutations in this same gene also cause a pure
cardiovascular disorder known as “familial supravalvar
aortic stenosis” (Eisenbert et al. 1964; Ewart et al. 1994;
Furthmayr and Francke 1997; Morris 1998). Finally,
Ehlers-Danlos syndrome, with its abnormalities of the
aorta and mitral valve that are associated with skeletal
abnormalities (Tsipouras et al. 1986; DePaepe et al.
1997; Michalickova et al. 1998) and osteogenesis im-
perfecta, has associated skeletal and vascular abnor-
malities that are due to mutations in collagen genes
(Willing et al. 1994). Thus, the common final pathway
involved in aortic and mitral valve abnormalities asso-
ciated with connective-tissue disorders appears to be
genes encoding connective-tissue proteins. Therefore, it
seems reasonable to suggest that pure MMVP could arise
from abnormalities of genes encoding either members of
this family of proteins or products that interact in the
cascade of these connective-tissue functions. As the genes
for this genetically heterogeneous disorder are identified,
the utility of this common-pathway concept will become
either apparent or discredited. In either case, knowledge
of the affected genes should allow for a better under-
standing of the clinical spectrum and potentially should
allow for improved clinical care of affected patients. The
study by Disse and colleagues is an excellent first step.
Electronic-Database Information
Accession numbers and URL for data in this article are as
follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim (for MVP [MIM 147700])
References
Albert JS, Sabik J, Cosgrove DM (1998) Mitral valve disease.
In: Topol EJ (ed) Textbook of cardiovascular medicine. Lip-
pincott-Raven, Philadelphia, pp 519–528
Bareiss P (1976) Familial forms of the mid-end systolic click
and murmur syndrome with deviations of left ventricular
kinetics. Arch Mal Coeur Vaiss 69:71–81
Barlow JB, Pocock WA (1979) Mitral valve prolapse, the spe-
cific billowing mitral leaflet syndrome, or an insignificant
non-ejection systolic click. Am Heart J 97:277–285
Barlow JB, Pocock WA, Marchand P, Denny M (1963) The
significance of late systolic murmur. Am Heart J 66:443–452
Beuren AJ (1972) Supravalvular aortic stenosis: a complex
syndrome with and without mental retardation. Birth De-
fects 8:45–56
Boudarias JP (1991) Mitral valve prolapse: a severe abnor-
mality? Arch Mal Coeur Vaiss 84:981–986
Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J,
Lessana A, D’Allaines C, et al (1980) Reconstructive surgery
of mitral valve incompetence: ten-year appraisal. J Thorac
Cardiovasc Surg 79:338–348
1240 Am. J. Hum. Genet. 65:1238–1241, 1999
Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada R, Brugada
P, Potenza D, et al (1998) Genetic basis and molecular mech-
anism for ventricular fibrillation. Nature 392:293–296
Cooper MJ, Abinader EG (1981) Family history in assessing
the risk for progression mitral valve prolapse: report of a
kindred. Am J Dis Child 135:647–649
DePaepe A, Nuytinck L, Hausser I, Anton-Lamprecht I, Nae-
yaert J-M (1997) Mutations in the COL5A1gene are causal
in the Ehlers-Danlos syndromes I and II. Am J Hum Genet
60:547–554
Devereux RB, Brown WT, Kramer-Fox R, Sachs I (1982) In-
heritance of mitral valve prolapse: effect of age and sex on
gene expression. Ann Intern Med 97:826–832
Disse S, Abergel E, Berrebi A, Houot A-M, LeHenzey J-Y,
Diebold B, Guize L, et al (1999) Mapping of a first lo-
cus for autosomal dominant myxomatous mitral valve pro-
lapse to chromosome 16p11.2q-p12.1. Am J Hum Genet
65:1242–1251 (in this issue)
Eisenbert R, Young D, Jacobson B, Boito A (1964) Familial
supravalvular aortic stenosis. Am J Dis Child 108:341–347
Ewart AK, Jin W, Atkinson D, Morris CM, Keating MT (1994)
Supravalvular aortic stenosis associated with a deletion dis-
rupting the elastin gene. J Clin Invest 93:1071–1077
Ewart AK Morris CA, Atkinson D, Jin W, Sternes K, Spallone
P, Stock AD, et al (1993) Hemizygosity at the elastin locus
in a developmental disorder, Williams syndrome. Nat Genet
5:11–16
Frable WJ (1969) Mucinous degeneration of the cardiac valves:
the “floppy valve” syndrome. J Thorac Cardiovasc Surg 58:
62–70
Furthmayr H, Francke U (1997) Ascending aortic aneurysm
with or without features of Marfan syndrome and other
fibrillinopathies: new insights. Semin Thorac Cardiovasc
Surg 9:191–205
Glesby MJ, Pyeritz RE (1989) Association of mitral valve pro-
lapse and systemic abnormalities of connective tissue: a phe-
notypic continuum. JAMA 262:523–528
Henney AM, Tsipouras P, Schwartz RC, Child AH, Devereux
RB, Leech GJ (1989) Genetic evidence that mutations in the
COL1A1, COLIA2, COL3A1, or COL5A2 collagen genes
are not responsible for mitral valve prolapse. Br Heart J 61:
292–299
Kern WH, Tucker BL (1972) Myxoid changes in cardiac
valves: pathologic, clinical and ultrastructural studies. Am
Heart J 84:294–301
Kyndt F, Schott JJ, Trochu JN, Baranger F, Herbert O, Scott
V, Fressinaud E, et al (1998) Mapping of X-linked myxo-
matous valvular dystrophy to chromosome Xq28. Am J
Hum Genet 62:627–632
Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi
M, Tsipouras P, et al (1991) Linkage of Marfan syndrome
and a phenotypically related disorder to two different fi-
brillin genes. Nature 352:330–334
Levine RA, Stathosgiannis E, Newell JB, Harrigan P, Weyman
AE (1988) Reconsideration of echocardiographic standards
for mitral valve prolapse: lack of association between leaflet
displacement isolated to the apical four chamber view and
independent echocardiographic evidence of abnormality. J
Am Coll Cardiol 11:1010–1019
Levy D, Savage D (1987) Prevalence and clinical features of
mitral valve prolapse. Am Heart J 113:281–1290
Maron BJ (1997) Hypertrophic cardiomyopathy. Lancet 350:
127–133
Michalickova K, Susic M, Willing MC, Wenstrup RJ, Cole
WG (1998) Mutations of the a2 (V) chain of type V collagen
impair matrix assembly and produce Ehlers-Danlos syn-
drome type I. Hum Mol Genet 7:249–255
Michels VV, Driscoll DJ, Miller FA Jr (1985) Familial aggre-
gation of idiopathic dilated cardiomyopathy. Am J Cardiol
55:1232–1233
Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll
DJ, Burnett JC, et al (1992) The frequency of familial dilated
cardiomyopathy in a series of patients with idiopathic di-
lated cardiomyopathy. N Engl J Med 326:77–82
Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P,
Kruse TA, Gregersen N, et al (1999) a-Cardiac actin is a
novel disease gene in familial hypertrophic cardiomyopathy.
J Clin Invest 103:R39–R43
Morris CA (1998) Genetic aspects of supravalvular aortic ste-
nosis. Curr Opin Cardiol 13:214–219
Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup
DM, Tajik AJ (1985) Echocardiographically documented
mitral valve prolapse. N Engl J Med 313:1305–1309
Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT
(1998) Actin mutation in dilated cardiomyopathy, a heri-
table form of heart failure. Science 280:750–752
Perloff JK, Child JS, Edwards JS, Edwards JE (1986) New
guidelines for the clinical diagnosis of mitral valve prolapse.
Am J Cardiol 57:1124–1129
Putnam EA, Zhang H, Ramirez F, Milewicz DM (1995) Fi-
brillin-2 (FBN2) mutations result in the Marfan-like disor-
der, congenital contractural arachnodactyly. Nat Genet 11:
456–458
Shappell SD, Marshall CE, Brown RE, Bruce TA (1973) Sud-
den death and the familial occurrence of mid-systolic click,
late systolic murmur syndrome. Circulation 48:1128–1134
Sood SR, Eldadah ZA, Krause WL, McIntosh I, Dietz HC
(1996) Mutation in fibrillin-1 and the marfanoid-cranio-
synostosis (Shprintzen-Goldberg) syndrome. Nat Genet 12:
209–211
Strahan NV, Murphy EA, Fortuin NJ, Come PC, Humphries
JO (1983) Inheritance of the mitral valve prolapse syn-
drome: discussion on a three dimensional penetrance model.
Am J Med 74:967–972
Tamura K, Fukunda Y, Ishizaki M, Masuda Y, Yamanaka N,
Ferrans VJ (1995) Abnormalities in elastic fibers and other
connective-tissue components of floppy mitral valve. Am
Heart J 129:1149–1158
Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W,
Vosberg HP, Seidman JG, et al (1994) a-Tropomyosin and
cardiac troponin T mutations cause familial hypertrophic
cardiomyopathy: a disease of the sarcomere. Cell 77:
701–712
Towbin JA (1998) The role of cytoskeletal proteins in car-
diomyopathies. Curr Opin Cell Biol 10:131–139
Towbin JA, Bowles KR, Bowles NE (1999) Etiologies of car-
diomyopathy and heart failure. Nat Med 5:266–267
Towbin JA, Roberts R (1998) Cardiovascular diseases due to
Towbin: Invited Editorial 1241
genetic abnormalities. In: Schlant RC, Alexander RW (eds)
Hurst’s the heart. McGraw-Hill, New York, pp 1877–1924
Tsipouras P, Byers PH, Schwartz RC, Chu ML, Weil D, Pepe
G, Cassidy SB, et al (1986) Ehlers-Danlos syndrome type
IV: cosegregation of the phenotype to a COL3A1 allele of
type III procollagen. Hum Genet 74:41–46
Virmani R, Atkinson JB, Forman MB, Robinowitz M (1987)
Mitral valve prolapse. Hum Pathol 18:596–602
Wang Q, Bowles NE, Towbin JA (1998) The molecular basis
of long QT syndrome and prospects for therapy. Mol Med
Today 4:382–388
Weiss AN, Mimbs JW, Ludbrook PA, Sobel BE (1975) Echo-
cardiographic detection of mitral valve prolapse, exclusion
of false positive diagnosis and determination of inheritance.
Circulation 52:1091–1096
Williams JCP, Barratt-Boyers BG, Lowe JB (1961) Supraval-
vular aortic stenosis. Circulation 24:1311–1318
Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL,
Pitts SH, Arikat H, et al (1994) Osteogenesis imperfecta type
I: molecular heterogeneity for COL1A1 null alleles of type
I collagen. Am J Hum Genet 55:638–647
Zuppiroli A, Roman MJ, O’Grady M, Devereux RB (1998) A
family study of anterior mitral leaflet thickness and mitral
valve prolapse. Am J Cardiol 82:823–826
